

# Mamta K Jain

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8278742/publications.pdf>

Version: 2024-02-01

110  
papers

4,582  
citations

172457

29  
h-index

110387

64  
g-index

111  
all docs

111  
docs citations

111  
times ranked

8154  
citing authors

#	ARTICLE	IF	CITATIONS
1	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 795-807.	27.0	1,398
2	A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 905-914.	27.0	357
3	Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.–Canadian multicenter study. <i>Journal of Hepatology</i> , 2007, 47, 527-537.	3.7	231
4	Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 156.	7.4	161
5	Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2021, 73, e3572-e3605.	5.8	123
6	Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1365-1376.	10.7	119
7	Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. <i>Lancet HIV</i> , 2017, 4, e536-e546.	4.7	101
8	Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 951-963.	10.7	99
9	Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 941-950.	10.7	83
10	Changes in Mortality Related to Human Immunodeficiency Virus Infection: Comparative Analysis of Inpatient Deaths in 1995 and in 1999–2000. <i>Clinical Infectious Diseases</i> , 2003, 36, 1030-1038.	5.8	80
11	Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. <i>Clinical Infectious Diseases</i> , 2016, 63, 1668-1676.	5.8	76
12	Infectious Diseases Society of America Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients With Suspected or Known Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2020, . . .	5.8	75
13	Suppression of HBV by Tenofovir in HBV/HIV Coinfected Patients: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e68152.	2.5	75
14	Race/ethnicity and insurance status disparities in access to direct acting antivirals for hepatitis C virus treatment. <i>American Journal of Gastroenterology</i> , 2018, 113, 1329-1338.	0.4	62
15	The RADAR Study: Week 48 Safety and Efficacy of Raltegravir Combined with Boosted Darunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health. <i>PLoS ONE</i> , 2014, 9, e106221.	2.5	59
16	Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response. <i>Journal of Viral Hepatitis</i> , 2007, 14, 176-182.	2.0	58
17	Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels. <i>Annals of Internal Medicine</i> , 2022, 175, 234-243.	3.9	56
18	Gamma/Delta T-Cell Functional Responses Differ after Pathogenic Human Immunodeficiency Virus and Nonpathogenic Simian Immunodeficiency Virus Infections. <i>Journal of Virology</i> , 2008, 82, 1155-1165.	3.4	49

#	ARTICLE	IF	CITATIONS
19	Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. <i>General Hospital Psychiatry</i> , 2013, 35, 122-128.	2.4	48
20	Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial. <i>Lancet, The</i> , 2022, 399, 530-540.	13.7	48
21	Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study. <i>BMC Medicine</i> , 2017, 15, 204.	5.5	46
22	Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting Antiviral Period?. <i>Hepatology</i> , 2019, 69, 51-63.	7.3	45
23	The Editor's I on Disease Development. <i>Trends in Genetics</i> , 2019, 35, 903-913.	6.7	42
24	Do HIV Care Providers Appropriately Manage Hepatitis B in Coinfected Patients Treated with Antiretroviral Therapy?. <i>Clinical Infectious Diseases</i> , 2007, 44, 996-1000.	5.8	38
25	Micro-RNA-122 levels in acute liver failure and chronic hepatitis C. <i>Journal of Medical Virology</i> , 2014, 86, 1507-1514.	5.0	38
26	Influence of HIV Infection on the Natural History of Hepatocellular Carcinoma: Results From a Global Multicohort Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 296-304.	1.6	36
27	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study. <i>American Journal of Gastroenterology</i> , 2019, 114, 746-757.	0.4	33
28	Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults. <i>Journal of Viral Hepatitis</i> , 2013, 20, 708-714.	2.0	32
29	Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. <i>Antiviral Research</i> , 2019, 170, 104543.	4.1	32
30	Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors. <i>HIV Medicine</i> , 2007, 8, 491-497.	2.2	31
31	Half of 30-Day Hospital Readmissions Among HIV-Infected Patients Are Potentially Preventable. <i>AIDS Patient Care and STDs</i> , 2015, 29, 465-473.	2.5	31
32	Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine. <i>Clinical Infectious Diseases</i> , 2014, 58, 555-563.	5.8	30
33	Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization. <i>Clinical Trials</i> , 2017, 14, 264-276.	1.6	30
34	Drug-Induced Liver Injury Associated with HIV Medications. <i>Clinics in Liver Disease</i> , 2007, 11, 615-639.	2.1	29
35	Change in Fibrosis Score as a Predictor of Mortality Among HIV-Infected Patients with Viral Hepatitis. <i>AIDS Patient Care and STDs</i> , 2012, 26, 73-80.	2.5	29
36	Evaluation of a Multifaceted Intervention to Reduce Health Disparities in Hepatitis C Screening: A Pre-Post Analysis. <i>Hepatology</i> , 2019, 70, 40-50.	7.3	29

#	ARTICLE	IF	CITATIONS
37	Hepatitis B virus genotype G: Prevalence and impact in patients coinfected with human immunodeficiency virus. <i>Journal of Medical Virology</i> , 2011, 83, 1551-1558.	5.0	28
38	Biliary parasites: Diagnostic and therapeutic strategies. <i>Current Treatment Options in Gastroenterology</i> , 2008, 11, 85-95.	0.8	26
39	Rudhira/BCAS3 is a cytoskeletal protein that controls Cdc42 activation and directional cell migration during angiogenesis. <i>Experimental Cell Research</i> , 2012, 318, 753-767.	2.6	26
40	Role of ribavirin in HCV treatment response: now and in the future. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 673-683.	1.8	25
41	Patient perspectives on hepatitis C and its treatment. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 74-81.	1.6	25
42	Missed Initial Medical Visits: Predictors, Timing, and Implications for Retention in HIV Care. <i>AIDS Patient Care and STDs</i> , 2017, 31, 213-221.	2.5	23
43	Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Coinfected Adults. <i>Hepatology</i> , 2020, 71, 411-421.	7.3	23
44	Acute bacterial cholangitis. <i>Current Treatment Options in Gastroenterology</i> , 2006, 9, 113-121.	0.8	21
45	Entecavir can select for M184V of HIV-1: a case of an HIV/hepatitis B (HBV) naïve patient treated for chronic HBV. <i>Aids</i> , 2007, 21, 2365-2366.	2.2	21
46	Clinical and Sociobehavioral Prediction Model of 30-Day Hospital Readmissions Among People With HIV and Substance Use Disorder: Beyond Electronic Health Record Data. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, 330-341.	2.1	21
47	The albuminâ€bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 95-103.	3.7	20
48	A Randomized Study of Antiviral Medication Switch at Lower-Versus Higher-Switch Thresholds: AIDS Clinical Trials Group Study A5115. <i>Antiviral Therapy</i> , 2007, 12, 531-541.	1.0	18
49	Evolution of hepatitis C virus NS5A region in breakthrough patients during pegylated interferon and ribavirin therapy. <i>Journal of Viral Hepatitis</i> , 2010, 17, 208-216.	2.0	17
50	Faldaprevir and pegylated interferon $\alpha$ -2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. <i>Aids</i> , 2015, 29, 571-581.	2.2	17
51	Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S63-S69.	4.0	17
52	Infectious Diseases Society of America Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients With Suspected or Known Coronavirus Disease 2019. <i>Clinical Infectious Diseases</i> , 2021, , .	5.8	16
53	Presentation, Treatment, and Clinical Outcomes of Patients With Hepatocellular Carcinoma, With and Without Human Immunodeficiency Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1284-1290.	4.4	15
54	An empirical study of alcohol consumption by patients considering HCV treatment. <i>American Journal of Drug and Alcohol Abuse</i> , 2014, 40, 484-489.	2.1	15

#	ARTICLE	IF	CITATIONS
55	Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2021, 73, e3275-e3285.	5.8	15
56	Patient and provider-level barriers to hepatitis C screening and linkage to care: A mixed-methods evaluation. <i>Journal of Viral Hepatitis</i> , 2020, 27, 680-689.	2.0	15
57	Case Report: Aminotransferase Elevation in HIV/Hepatitis B Virus Co-infected Patients Treated with Two Active Hepatitis B Virus Drugs. <i>AIDS Patient Care and STDs</i> , 2006, 20, 817-822.	2.5	14
58	Host-Based Ribavirin Resistance Influences Hepatitis C Virus Replication and Treatment Response. <i>Journal of Virology</i> , 2011, 85, 7273-7283.	3.4	14
59	Pegylated Interferon Fractal Pharmacokinetics: Individualized Dosing for Hepatitis C Virus Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 1115-1120.	3.2	14
60	Gamma/Delta T Cell mRNA Levels Decrease at Mucosal Sites and Increase at Lymphoid Sites Following an Oral SIV Infection of Macaques. <i>Current HIV Research</i> , 2008, 6, 520-530.	0.5	13
61	Mortality in Patients Coinfected with Hepatitis B Virus and HIV: Could Antiretroviral Therapy Make a Difference?. <i>Clinical Infectious Diseases</i> , 2009, 48, 1772-1774.	5.8	12
62	A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America. <i>Hepatology</i> , 2021, 74, 1174-1189.	7.3	11
63	Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. <i>HIV Medicine</i> , 2015, 16, 109-118.	2.2	10
64	An effectiveness study of group psychoeducation for hepatitis C patients in community clinics. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 679-685.	1.6	10
65	Significant Increase in Risk of Fibrosis or Cirrhosis at Time of HCV Diagnosis for Hispanics With Diabetes and Obesity Compared With Other Ethnic Groups. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1356-1363.	4.4	10
66	Predictors for Poor Linkage to Care Among Hospitalized Persons Living with HIV and Co-Occurring Substance Use Disorder. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 406-414.	1.1	10
67	Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV-HCV co-infected patients. <i>Journal of Viral Hepatitis</i> , 2015, 22, 25-36.	2.0	9
68	Treatment of Hepatitis C in HIV-Infected Patients: Moving Towards an Era of All Oral Regimens. <i>AIDS Patient Care and STDs</i> , 2015, 29, 329-337.	2.5	9
69	Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) Fixed-Dose Combination (FDC) Compared With Ritonavir-Boosted Atazanavir (ATV/r) Plus Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC) in Treatment-Naive Women With Human Immunodeficiency Virus (HIV)-1 Infection (ARIA Study): Analyses by Race Subgroups. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	9
70	Low Rates of Hepatitis B Virus Treatment Among Treatment-Eligible Patients in Safety-Net Health Systems. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 360-368.	2.2	8
71	Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems. <i>American Journal of Gastroenterology</i> , 2021, 116, 1465-1475.	0.4	8
72	Incidence and Predictors of Hepatitis B Surface Antigen Clearance in HIV Patients: A Retrospective Multisite Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab116.	0.9	8

#	ARTICLE	IF	CITATIONS
73	Randomized Clinical Trial of Inreach With or Without Mailed Outreach to Promote Hepatitis C Screening in a Difficult-to-Reach Patient Population. <i>American Journal of Gastroenterology</i> , 2021, 116, 976-983.	0.4	8
74	Pegylated Interferon and Ribavirin Promote Early Evolution of Nonstructural 5A Protein in Individuals with Hepatitis C Who Demonstrate a Response to Treatment. <i>Journal of Infectious Diseases</i> , 2009, 200, 866-876.	4.0	7
75	A case of peritoneal histoplasmosis in a patient receiving chronic ambulatory peritoneal dialysis. <i>Mycoses</i> , 2012, 55, 99-100.	4.0	7
76	Prospective Longitudinal Substance Use Patterns in Patients Preparing for Hepatitis C Treatment. <i>Journal of Dual Diagnosis</i> , 2018, 14, 60-69.	1.2	7
77	Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064). <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab334.	0.9	7
78	Patient Navigation Increases Linkage to Care and Receipt of Direct-acting Antiviral Therapy in Patients with Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 988-994.e2.	4.4	7
79	A single nucleotide polymorphism in IL28B affects viral evolution of hepatitis C quasispecies after pegylated interferon and ribavirin therapy. <i>Journal of Medical Virology</i> , 2012, 84, 1913-1919.	5.0	6
80	Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial. <i>American Journal of Hypertension</i> , 2020, 33, 43-52.	2.0	6
81	An assessment of concurrent drug and alcohol use among patients seeking treatment for hepatitis C. <i>Annals of Clinical Psychiatry</i> , 2016, 28, 31-6.	0.6	6
82	Health Beliefs and Co-morbidities Associated with Appointment-Keeping Behavior Among HCV and HIV/HCV Patients. <i>Journal of Community Health</i> , 2016, 41, 30-37.	3.8	5
83	The risk of depression among racially diverse people living with HIV: the impact of HIV viral suppression. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 645-653.	1.2	5
84	Signature molecules expressed differentially in a liver disease stage-specific manner by HIV-1 and HCV co-infection. <i>PLoS ONE</i> , 2018, 13, e0202524.	2.5	4
85	Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV-HIV Co-infected Adults. <i>Digestive Diseases and Sciences</i> , 2022, 67, 676-688.	2.3	4
86	Evaluation and treatment of the patient coinfecting with hepatitis B and HIV. <i>Current HIV/AIDS Reports</i> , 2008, 5, 103-111.	3.1	3
87	HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. <i>PLoS ONE</i> , 2020, 15, e0224875.	2.5	3
88	Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment. <i>Journal of Clinical and Experimental Hepatology</i> , 2020, 10, 114-123.	0.9	2
89	A Multicomponent Intervention to Reduce Readmissions Among People With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, 161-169.	2.1	2
90	Predictors of linkage to hepatitis C virus care among people living with HIV with hepatitis C infection and the impact of loss to HIV follow-up. <i>Health Science Reports</i> , 2022, 5, .	1.5	2

#	ARTICLE	IF	CITATIONS
91	HBV transcription and translation persist despite viral suppression in HBV&HIV co&infected patients on antiretroviral therapy. <i>Hepatology</i> , 2023, 77, 594-605.	7.3	2
92	Pattern of Hepatitis B Virus (HBV) Core Antigen (HB CAG +) and Surface Antigen (HBSAG) Staining in Patients Co-Infected with Human Immunodeficiency Virus (HIV). <i>Gastroenterology</i> , 2017, 152, S1070.	1.3	1
93	Educating Primary Care Providers and Associate Care Providers About Hepatitis C Screening of Baby Boomers: a Multi-practice Study. <i>Journal of Cancer Education</i> , 2022, 37, 217-223.	1.3	1
94	Access to Coronavirus Disease 2019 Clinical Trials by English and Non-English Speakers Is Needed. <i>Clinical Infectious Diseases</i> , 2020, 71, 2298-2299.	5.8	1
95	Self-efficacy as a mediator of patient navigation interventions to engage persons living with HIV and substance use. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108567.	3.2	1
96	Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109265.	3.2	1
97	Gonococcal Retropharyngeal Abscess Complicated by Cervical Osteomyelitis in a Patient with Acquired Immunodeficiency Syndrome. <i>Infectious Diseases in Clinical Practice</i> , 2001, 10, 275-278.	0.3	0
98	Pharmacotherapy of Chronic Hepatitis B in Adults: Focus on Tenofovir Disoproxil Fumarate. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S1161.	0.1	0
99	Serum miR-122 and Human Genomic DNA in Patients With Drug-Induced Acute Liver Failure or With Chronic Hepatitis C. <i>Gastroenterology</i> , 2011, 140, S-951.	1.3	0
100	Thirty-Day Readmissions Among HIV-Infected Individuals at a Safety-Net Hospital: Predictors and Preventability. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.9	0
101	High Prevalence of Significant Co-Morbidities and Low Rates of Receiving Hepatitis C Virus Treatment among Ethnically Diverse, High Risk, Urban Safety-Net Hospital Populations in California and Texas. <i>Gastroenterology</i> , 2017, 152, S1189.	1.3	0
102	Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Coinfected with Human Immunodeficiency Virus (HIV). <i>Gastroenterology</i> , 2017, 152, S27.	1.3	0
103	2233. Hepatitis C Eradication: Who Is Being Left Behind in the HIV Population?. <i>Open Forum Infectious Diseases</i> , 2018, 5, S660-S660.	0.9	0
104	2207. Barriers to HCV Treatment in a Safety-Net Hospital System. <i>Open Forum Infectious Diseases</i> , 2018, 5, S651-S652.	0.9	0
105	THU-238-Low rates of antiviral therapy among treatment-eligible adults with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019, 70, e269-e270.	3.7	0
106	Incidence and predictors of hepatitis B surface antigen clearance among people living with HIV and hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, S591.	3.7	0
107	Initiation of Antiretroviral Therapy in the Hospital Is Associated With Linkage to Human Immunodeficiency Virus (HIV) Care for Persons Living With HIV and Substance Use Disorder. <i>Clinical Infectious Diseases</i> , 2020, 73, e1982-e1990.	5.8	0
108	OUP accepted manuscript. <i>Clinical Infectious Diseases</i> , 2021, , .	5.8	0

#	ARTICLE	IF	CITATIONS
109	89976 ASSESSING PROTEIN BIOMARKERS ROLE IN CVD RISK PREDICTION IN PERSONS LIVING WITH HIV (PWH). Journal of Clinical and Translational Science, 2021, 5, 47-48.	0.6	0
110	Treatment of Hepatitis B in HIV-Infected Persons. , 2012, , 141-149.		0